drugset / Trial / NCT00724022

Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation

NCT00724022

RandomizedParallel-groupOpen-labelPrevention

Summary

Current practice of immune suppressive standard therapy after renal transplantation in non-risk patients is a triple therapy consisting of steroids, a calcineurin inhibitor and MMF. The aim of this clinical trial is to combine a reduction of CNI using tacrolimus and a concept of not using steroids in order to establish an immunosuppressive regimen in immunologically non-risk patients that is efficient and causes as few side effects as possible.

Timeline

Start
2008-06
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Basiliximab Monoclonal antibody
Subject Prednisolone Other / unclassified
Subject rATG Unknown
Background Mycophenolate Mofetil Small molecule
Background Tacrolimus Small molecule